As Health Disparities “Weave Their Way Through Hypertension,” New Agents Are on the Way
August 8th 2022Coverage from the 2022 Congress of the American Society for Preventive Cardiology (ASPC) in Louisville, Kentucky, featuring 3 experts on aspects of hypertension treatment: Keith C. Ferdinand, MD, of Tulane University School of Medicine; Kim Allan Williams, MD, of the University of Louisville; and George C. Bakris, MD, of the University of Chicago Medicine.
Read More
Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer
August 6th 2022The approval came exactly 2 months after results from the landmark DESTINY-Breast04 trial showed that the antibody drug conjugate reduced the risk of disease progression or death by 50% compared with chemotherapy for HER2-low patients with both hormone receptor (HR)–positive and HR-negative disease.
Read More
Young Adults With SCD Show Better Hydroxyurea Adherence Than Children, Adolescents
August 6th 2022With adherence estimated at less than 50% in children, adolescents, and young adults, a recent study stresses the importance of treatment adherence for patients with sickle cell disease receiving hydroxyurea and the benefit for those who do.
Read More
Obesity, Physical Inactivity Linked With Higher Risk for Activity Limits in Asthma
August 5th 2022Patients with asthma and all types of obesity, or with all types of obesity and physical inactivity, have an increased risk for limited activity of daily living, according to the results of a recent study.
Read More
Advocate Addresses Factors Physicians Should Consider in Managing Hidradenitis Suppurativa
August 5th 2022Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on the need for awareness among physicians and patients on the clinical features of HS in regard to both physical and psychosocial burdens.
Watch
Pharmaceutical Research and Manufacturers of America (PhRMA) is threatening swift retaliation if a reconciliation package that includes drug pricing is passed; New York health officials urge polio vaccinations after polio virus was found in 7 wastewater samples; conjoined twins in Brazil were separated via surgery using virtual reality.
Read More
Three CAR T-Cell Trials, 2 Outcomes, for Second-line LBCL Therapy
August 4th 2022Both the ZUMA-7 trial for axicabtagene ciloleucel—approved for second-line treatment earlier this year—and the TRANSFORM trial for lisocabtagene maraleucel showed significant improvement over standard of care for large B cell lymphoma (LBCL), while the BELINDA trial for tisagenlecleucel did not.
Read More
Phase 3 Study: Zanubrutinib Improves PFS Over Chemoimmunotherapy in Untreated CLL, SLL
August 4th 2022The findings, coming from the phase 3 SEQUOIA study, found that the next-generation, selective Bruton tyrosine kinase inhibitor had superior efficacy versus chemoimmunotherapy and demonstrated an acceptable safety profile among 600 older patients with comorbidities.
Read More
NGF-Based MRD Assessment Demonstrates Potential to Predict MM Disease Progression
August 4th 2022Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.
Read More